Response: We note that in the CY 2026 OPPS/ASC proposed rule (90 FR 33775), we proposed to utilize the same file format requirementsthe QRDA standardapplied in the Hospital IQR, OQR, and Medicare Promoting Interoperability Programs (85 FR 58940, 86 FR 42262, and 80 FR 49706, respectively)
Safety Considerations and Provider Guidance for GLP-1 Selection All GLP-1 drug names carry similar safety profiles: nausea, vomiting, and gastrointestinal disturbances are common early side effects
A case of severe glutathione synthetase deficiency with novel GSS mutations
This treatment should be provided within specialist weight management services, is typically time-limited (generally up to 2 years), and must be part of a comprehensive programme including dietary modification, increased physical activity, and behavioural support